Xenotransplantation by Stevens, Sean
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 16
Xenotransplantation
Sean Stevens
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.76502
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
  t v s
Additional infor ation is available at the end of the chapter
Abstract
Xenotransplantation, defined as the transfer of cells, tissues or organs between spe-
cies, has been a subject of significant interest for decades as a response to the increasing 
demand for biological materials to treat patients. In this review, the history and recent 
progress in xenotransplantation research will be discussed, including the immunological 
challenges that need to be overcome and the molecular biological methods which are 
required to allow the complex genome engineering to meet the critical need for organs.
Keywords: xenotransplantation, immune rejection, swine, transgene, gene editing,  
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1. Introduction
Over the course of the past 100 years, the rapid progress in drug development and surgical 
techniques has created a paradox for the area of transplantation medicine. Surgical protocols 
have become more successful and medicines have overcome many mechanisms of chronic 
rejection and allowed increased survival of transplant patients. However, the number of 
organs available for transplant has remained essentially constant. In addition, not all organs 
available through donation are viable for transplant. Organs such as lung, which are more 
prone to damage due to trauma, disease or deterioration, are available in drastically reduced 
numbers compared with heart or kidneys. Therefore, while there is an increasing number 
of patients who would survive and thrive long-term after organ transplantation, the lim-
ited number of organs available means a smaller percentage of eligible patients can actually 
undergo transplant surgery.
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A hard truth about human organ donation is that even with exponential increases in donor 
numbers, it is unlikely that the organ shortage would be relieved. The diversity of the human 
species, paired with the efficiency of the immune system, significantly reduces the chances 
that a given organ will be compatible with the patients in greatest need. Although immuno-
suppressive drugs can enhance length of survival, chronic rejection remains a risk the greater 
the mismatch between organ and patient. Furthermore, the donor geographic proximity, 
organ size and timing of availability of a compatible organ with a matching patient may be 
limiting. Thus, even as human organ donation continues to be optimized, there remains an 
immense need for additional organs above and beyond the availability of human donors.
In order to address the above concerns and provide sufficient numbers of compatible organs, 
a number of approaches, both biological and mechanical, are being actively explored. Use 
of animal organs provides solutions to the challenges of availability and function. Multiple 
mammalian species possess organs which may substitute effectively for their human analogs 
and, in the case of agricultural species, can be rapidly bred in sufficient numbers to over-
come organ shortages. Through use of controlled facilities, production of animals can be regu-
lated and disease exposure eliminated. Additionally, careful breeding schedules can provide 
organs of appropriate size for any given patient on a predictable schedule for optimal timing 
of surgery. Finally, recent advancements in DNA sequencing and assembly and genome engi-
neering technologies, paired with the advanced understanding of the cellular and molecular 
immunology responses in transplant rejection, allow the creation of animals which could pro-
vide an unlimited supply of rejection-free organs.
2. Early beginnings
Examples of xenotransplantation can be found recorded as early as the seventeenth century, in 
which the transfusion of blood from animals into human patients was described [1]. In the eigh-
teenth century, more complex tissues such as skin were tested as grafts in human patients [2]. 
In 1905, Princeteau transferred rabbit kidney sections into a child with immediate positive 
results, however, after 16 days the child died of pulmonary complications [3]. Soon thereaf-
ter, two kidney xenotransplants were attempted, with one patient receiving an organ from 
goat, the other from pig. Unlike Princeteau’s experiment, neither organs functioned and both 
apparently failed due to thrombosis [4]. Similarly, an attempt by Unger in 1910 to transplant 
kidneys from a chimpanzee into humans led to failure due to thrombosis in about a day [5]. 
In 1923, Neuhof transplanted a kidney from a lamb into a human patient, allowing the patient 
to survive 9 days [6].
In the early twentieth century, an odd offshoot of xenotransplantation was created due to 
interest in “rejuvenation” via transplant of animal testis in human males, as demonstrated by 
Voronoff in Russia [7] and Brinkley in the US [8] using chimpanzee or goat testis, respectively. 
So popular was the use of goat testis in the US, an entire radio empire was built around adver-
tising the services, with many patients claiming enhanced fertility and sexual function [8].
The field of immunology developed in parallel with surgical approaches to xenotransplanta-
tion. As the mechanisms of immune rejection were better defined, the enormity of the chal-
lenges facing transplant of organs between members of the same species were recognized. 
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During and after WWII, pharmaceutical companies created a series of increasingly effective 
immunosuppressive drugs which could inhibit some rejection responses, renewing interest 
in xenotransplantation.
3. First attempts at human xenotransplantation with primate organs
During 1963–1964, Reemstma carried out a series of transplants into 13 human patients using 
chimpanzee kidneys, with one patient surviving 9 months after transplant surgery [9]. The 
need for these experiments was driven in part by the desperate human organ shortage and 
lack of alternatives. Cadaveric organs often proved insufficient in quality, and volunteer 
human kidney donation, high risk at the time, was untenable for ethical and legal reasons. 
Although chronic dialysis had been demonstrated by the early 1960s, it was not widely avail-
able for patient treatment [10]. Therefore, despite the risks, xenotransplantation was consid-
ered a potentially viable solution.
Reemstma was not alone in exploring xenotransplantation as a means to overcome critical 
organ shortages. Hume attempted transplanting a chimpanzee kidney into a human, but the 
organ failed to show renal function [11]. Hardy and team focused on heart, observing survival 
for only 2 hours after transplanting a chimpanzee heart into a human patient [12]. Starzl car-
ried out a series of transplants in human patients with baboon kidney [13] and livers, with 
variable results [14]. These seminal attempts at xenotransplantation showed that although sur-
gical techniques and immunosuppressive drug treatments had greatly improved, they were 
insufficient to address the multitude of challenges in overcoming the xenorejection response. 
Indeed, it was nearly a generation later before Bailey used a baboon heart for transplantation 
into an infant, who survived several weeks after receiving the organ [15].
4. A shift in species
Although the close evolutionary relationship between non-human primates and humans would 
suggest an advantage in using chimpanzee or baboon organs for xenotransplantation, clinical, 
practical and ethical considerations prevent them from being a viable option. Non-human primate 
organs do indeed function almost identically to human organs, but are subject to a variety of dis-
eases which are readily transmissible to humans [16]. Given the relatively fragile state of patients 
receiving multiple immunosuppressive drugs, the risk of primate zoonoses is too great. In addi-
tion, chimpanzees, baboons and many other non-human primates are impractical for large scale 
breeding. The low numbers of progeny of non-human primates limits the production of large 
numbers of animals by natural breeding or in vitro fertilization compared with agricultural spe-
cies. Finally, use of non-human primates as organ donors faces insurmountable ethical barriers.
A much more viable approach is the use of pig organs for xenotransplantation. Porcine organs 
are structurally and physiologically close to humans, and therefore can functionally substitute 
for analogous human organ functions. Unlike non-human primates, pigs are more evolution-
arily distant from humans and thus have a greatly reduced risk of transmission of diseases 
to human patients, which can be essentially eliminated through genetic manipulation [17]. 
Xenotransplantation
http://dx.doi.org/10.5772/intechopen.76502
333
Husbandry techniques for pigs are extremely well-understood, with large litter sizes and 
rapid cycle times, allowing production of populations that could overcome organ shortages 
in a much shorter timeframe than possible with non-human primates. Furthermore, a suite 
of genome engineering technologies is available for use in pigs to make critical changes to 
enhance survival and function of the pig organ, while avoiding the human immune rejection 
response. In fact, the complex engineering approaches now available may actually provide 
organs with advantages over even closely-matched human organs.
5. Current status and challenges for xenotransplantation
A variety of academic, clinical and industrial institutions have made substantial progress in 
recent years in the understanding of the molecular mechanisms of the xenorejection response 
and the genetic modification of pigs to overcome these mechanisms [18]. Professional organiza-
tions are working with the FDA to develop guidelines for clinical use [19], with several groups 
indicating their intention to initiate clinical trials in the near term with porcine organs [20].
For xenotransplantation to become a viable routine human therapeutic option, there are a 
number of challenges that still need to be overcome. These challenges fall into two broad cat-
egories; the biology of the xenorejection responses and the engineering technologies needed 
to restructure the porcine genome to overcome these responses.
6. The immune system and rejection
The immune system is an evolutionarily ancient collection of structures, mechanisms and 
cells that detect and eliminate harmful organisms from the host. In older texts, the immune 
system is often described as distinguishing “self” from “non-self,” but more recent research 
demonstrates that there are a variety of roles for the microbiome (“non-self” micro-organisms 
resident within, on or around the host) in maintaining the health of the host organism. Thus, 
the host immune system must be able to not only identify and eliminate harmful pathogens, it 
must also tolerate the presence of a variety of beneficial bacteria, fungi and yeast [21]. Because 
transplantation of cells, tissues and organs is an unnatural situation created through delib-
erate medical intervention, the human immune response uses incredible precision to iden-
tify even closely related human cells as “non-self” and efficiently removing them, a process 
referred to as “immune rejection.” In general, the strength of the response is proportional to 
the degree of difference between the host and donor materials, therefore, when exposed to 
materials from an animal, the rejection response is much faster and stronger, increasing the 
challenge in controlling the immune response.
7. Xenotransplant rejection
Xenorejection is a much more exaggerated and rapid form of the allorejection response. 
Four overlapping and inter-related reactions occur temporally; hyperacute rejection (HAR), 
acute vascular rejection/acute humoral xenograft rejection (AVR/AHXR), acute cellular 
rejection (ACR) and chronic rejection (CR) (Figure 1) [22]. Although these processes can be 
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characterized as distinct stages based on histological and clinical data, each is due to highly 
interconnected pathways and mechanisms that are challenging to separate. In fact, these 
responses were defined as pathologic observations prior to development of more detailed 
analyses of the molecular immunology mechanisms.
HAR is primarily due to immediate binding of pre-existing host natural antibodies specific 
for xenoantigens expressed by the donor tissues. Antibody binding can activate the endo-
thelial cells, causing the release of immune activators, as well as inducing the complement-
mediated destruction of the endothelial layer, reducing the barrier function and allowing 
host cells to infiltrate the organ. Cell debris released by the damage to the endothelium and 
products of the complement cascade also stimulate coagulation and the innate inflammatory 
response. These pathways synergize during rejection to create stronger responses that are 
more pathogenic and can be less amenable to control.
AVR/AHXR, like HAR, is also mediated by host antibodies. However, instead of pre-existing 
natural antibodies, AVR/AHXR is often the result of humoral responses which lead to produc-
tion of antigen-specific antibodies. The AVR/AHXR is delayed due to the time it takes to induce 
Figure 1. Overview of the xeno-rejection response. The human immune response to xeno-organs initiates within minutes 
to hours with hyperacute rejection (HAR, upper right), in which pre-existing antibodies (Ab) in human serum bind to 
xenoantigens (xeno Ag) on the surface of the pig cells. This results in cell destruction and presentation of porcine antigens 
to human helper (TH) and cytolytic (TC) T cells, as well as groups of pro-inflammatory and pro-immunity cytokines 
and other soluble mediators. Activation of human helper T cells (TH) stimulates human B cells (B) over the course of 
days to weeks, resulting in production of induced antibodies (induced Ab) as part of the acute vascular rejection/acute 
humoral xenograft rejection (AVR/AHXR, lower right) response. These secondary antibodies are often more specific and 
higher affinity than the pre-existing human serum antibodies, and also cause cellular destruction of the xenograft. in 
parallel with AVR/AHXR, the acute cellular rejection response (ACR, lower left) is carried out by human NK cells (NK), 
macrophages (M) and the xenograft-specific cytolytic T cells (TC) recruited to the xeno-organ within days to weeks. 
The activated cells express a variety of molecules to attack the porcine cells, as well as secrete additional cytokines to 
recruit more human immune cells. After weeks to months, the human immune response may be again induced to react 
to the xeno-organ during chronic rejection (CR, upper left), leading to specific antibody (Ab) responses from B cells (B) 
or cytolytic T cell (TC) destruction. A large collection of cytokines, chemokines, complement and coagulation factors 
(center) play a key role in regulating the complex set of reactions occurring in every aspect of rejection.
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an adaptive immune response via germinal center reactions, typically days to weeks. Much like 
natural antibodies, the induced antibodies recognize components of the xeno-organ and, similar 
to HAR cause activation of the endothelial cells and their destruction via the complement sys-
tem. The specific antibody binding also attracts multiple elements of the cellular immune sys-
tem, such as NK cells and phagocytes, creating further damage of the target tissues and secreting 
soluble factors, such as cytokines and chemokines, which further enhance immune responses.
ACR includes predominantly cellular responses to the graft, such as T cell activation, which 
occur within days to weeks of organ transplant. Although ACR is well-established in allo-
transplant, the importance of ACR in the xenorejection response is not entirely clear. This 
may be due to either the more rapid activation of hematopoietic populations in HAR and 
AVR/AHXR compared with allotransplantation. However, some groups have proposed that 
reduction of the HAR and AVR/AHXR in earlier stages of xenorejection would unmask ACR 
which would otherwise be unnoticed amidst the earlier more pathogenic responses. In either 
case, ACR is expected to be substantially similar between allo- and xenotransplantation and 
thus more readily controlled by immunosuppressive drugs already in use for allotransplant.
CR is longer term, occurring within months or even years after transplantation. CR can be 
due to complications due to other immune activity, such as infection, or escape of humoral or 
cellular responses from immunosuppressive drug control. CR is well-understood in allotrans-
plant and effective treatments are available for control and reversal of CR.
HAR and AVR/AHXR are the most unique and most critical to address in xenotransplanta-
tion. These earlier reactions can greatly enhance later reactions, with some of the mechanis-
tic elements of the xenorejection response initiated even before the transplant surgery itself 
occurs. Therefore, it is essential to control the initiating events as early as possible in order 
to reduce the course of later responses. Much like the layers of an onion, removing one layer 
reveals the next, but as each layer is removed the overall size may be diminished.
The latter two responses, ACR and CR, are mechanistically similar between xeno- and allore-
jection responses [23]. Use of currently-available immunosuppressive drugs are believed to 
be able to control both responses as evidenced by the extensive data from allotransplants 
in humans. However, the speed and violence of the HAR and AVR reactions against xeno-
organs can greatly accelerate and strengthen ACR and CR. Thus, even well-established treat-
ments for allorejection may need to be reviewed as xenotransplantation proceeds toward 
clinical trials.
8. Innate and adaptive immunity in xenotransplantation
The immune system has two inter-related arms; the innate and the adaptive immune systems, 
both of which contribute to the rejection of xenotransplanted cells, tissues and organs. Although 
often described as separate, the systems have a large network of connections which are inter-
dependent, and thus are not completely distinct. Both systems utilize multiple mechanisms to 
protect the host, creating a series of defense layers of increasing specificity. When functioning 
properly, a given layer may not be 100% efficient, but in aggregate will capture the overwhelm-
ing majority of pathogens. In addition, the ability to detect subtle differences between highly 
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related cells has the potential benefit of identifying and eliminating cells with oncogenic muta-
tions, preventing tumors before they have a chance to establish themselves [21].
8.1. The innate immune system and xenorejection
The innate immune system is evolutionarily ancient, with related mechanisms found in both 
plants and animals. The innate immune system consists of relatively invariant mechanisms 
for the identification of pathogens, and, although less specific, is extremely rapid and strong 
in response. The rapidity of the innate immune system provides an immediate barrier to 
pathogen infiltration and infection of the host, limiting the pathogen burden and giving the 
adaptive immune system time to develop more specific responses [24].
The use of physical barriers is one of the most critical elements of innate immunity. Although 
organ transplant bypasses the skin as a protective layer, the endothelium of the blood vessels, 
which connect the organ to the host circulatory system, remains as the main interface between 
the human hematopoietic system and xeno-organ tissues. As such, many of the immediate 
mechanisms of the innate response are greatly influenced by the interactions between the 
human immune cells and the porcine endothelial cells. Once the human innate immune sys-
tem attacks the porcine endothelium, the barrier function is quickly lost, followed by rapid 
influx of human immune cells, pro-inflammatory infiltrates and edema, and then necrosis and 
destruction of the xeno-organ. It is important to note that the endothelium is an extremely 
active part of the immune response, which responds to soluble factor and cellular interactions 
to induce a variety of immune and inflammatory responses. Therefore, any efforts to improve 
the engraftment of xeno-organs must take into account the functional role of the endothelium 
in regulating the rejection response [25].
8.2. Inflammation
Inflammation is one of the earliest innate responses, driven by pattern recognition recep-
tors found on human immune cells which recognize damage-associated molecular patterns 
(DAMPs). The binding and signaling of DAMPs causes the immediate secretion of proin-
flammatory mediators, such as cytokines and chemokines, which attract additional innate 
immune cells and induce a variety of local responses which would be highly beneficial during 
an infection but destructive to xeno-organs. For example, vasodilation and increased vascu-
lar permeability, which would normally allow host immune cells greater access to tissue to 
rapidly eliminate pathogens, instead causes the xeno-tissue to be more quickly infiltrated 
by human innate immune cells, which in turn leads to more inflammation and destruction. 
Similarly, there are blood-borne proteinaceous biochemical cascades activated by inflamma-
tion, such as the coagulation and the complement systems, which further degrade xeno-organ 
function and survival [26].
8.3. Xenoantigens
The genes encoded by the porcine genome can encode proteins that are substantially differ-
ent from their human counterparts or may carry post-translational modifications which are 
not present in humans. Interestingly, some of these molecules, referred to as “xenoantigens”, 
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are recognized by pre-existing natural antibodies found in human serum. One subset of these 
antigens is the swine leukocyte antigens (SLA), which are the physical and functional equiva-
lent of the human leukocyte antigens (HLA). Much like the case for human allotransplant, 
the SLA genes are highly diverse and individual patients will have a variable level of cross-
reactive antibodies in their serum for a given set of SLA genes [27]. A separate group of xeno-
antigens are glycan molecules, such as Gal alpha (1,3) Gal and Neu5Gc, which are expressed 
in porcine, but not human, cells [28].
Although specific induced antibodies are produced by B cells as part of the adaptive response, 
the presence of pre-existing antibodies in human serum contributes to the innate response. 
The specific reasons for the existence of these human natural antibodies are not entirely clear. 
In the case of glycan structures, one hypothesis is that the molecules are related to those found 
in pathogens, and that the natural antibodies are cross-reactive to each. Alternately, consump-
tion of porcine materials in the human diet may induce antibody formation. Regardless of the 
specific source in human serum, xenotransplantion of porcine cells and tissues in humans 
leads to binding of these pre-existing natural antibodies, activation of complement and even-
tual destruction of target cells carrying the xenoantigens.
Several approaches have been taken to address xenoantigens, including cross-matching 
donors and recipients for reduced immunoreactivity, removal or modification of the xenoan-
tigen from the donor pig, or the reduction of the ability of the antibodies to induce the comple-
ment cascade. In the first case, typing of patients and porcine donors to find the best matches 
would be very similar to the current system used for determining allotranplant cross-reactiv-
ity [29]. Use of gene targeting or editing technologies can eliminate the genes encoding SLA or 
the enzymes required for expression of the relevant glycan. This has been proven to be highly 
effective for ablating the genes GGTA1 (the gene encoding alpha 1,3-galactosyltransferase 
essential for Gal alpha (1,3) Gal), CMAH (cytidine monophosphate-N-acetylneuraminic acid 
hydroxylase critical for Neu5Gc biosynthesis) and B4GALNT2 (beta 1,4 N-acetylgalactosam
inyltransferase). In each case, the elimination of the glycan leads to greatly reduced recogni-
tion of porcine cells by natural antibodies in human serum, and reduction in complement-
mediated destruction [28]. Unfortunately, as the number of antibody targets increases there 
is a risk that one or more of the xenoantigens alone or in combination may have essential 
functions which cannot be eliminated without damaging the development or function of the 
pig. Therefore, efforts to introduce more subtle mutation in SLA which remove immunogenic 
epitopes while leaving critical antigen-presentation functions intact, or even replacement of 
SLA with HLA, may be more effective.
The second approach, which is often used in combination with the first, is to reset the thresh-
old at which the complement cascade is activated, making it more difficult for the binding 
of human natural antibodies to targets on porcine cells to induce the complement cascade. 
There are a series of “complement regulatory proteins” (CRPs), such as CD46, CD55 and 
CD59, expressed on the cell surface which prevent complement activation by the inadvertent 
non-specific binding of human antibody to human cells [30]. By overexpressing one or more 
of the CRP molecules on the porcine endothelium, the amount of antibody binding required 
for complement activation is increased, which reduces the amount of antibody-mediated cell 
destruction due to human natural antibodies [31].
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8.4. Coagulation
Inflammation and vascular leakage, due to loss of endothelial barrier function, both induce 
coagulation, which normally is required to repair localized endothelial damage. In the case of 
xenotransplantion, the attack of the endothelium is rapidly occurring at multiple sites, there-
fore, coagulation spreads throughout the blood vessels in the xeno-organ and can overcome 
the normal control mechanism. The thrombosis produced by the procoagulant environment 
leads to occlusion of the vessels within the graft, known as thrombotic microangiopathy (TM). 
The lack of blood flow results in hypoxia and tissue damage and necrosis, further complicat-
ing transplant function. The relatively greater amount of endothelial injury and coagulation 
in xenotransplant therefore creates more frequent and extensive TM and contributes to the 
more rapid destruction of the graft [32].
In addition to physiological pathways induced by human innate immune responses, there are 
non-physiological activities caused by mismatches between porcine and human constituents 
of the coagulation cascade [33]. For example, porcine von Willebrand factor (vWF) has been 
shown to bind more avidly to the human GP1b receptor and activate human platelets, lead-
ing to coagulation and rapid loss of platelets from the circulation [34]. Ongoing efforts seek to 
engineer porcine vWF to eliminate the inappropriate interactions with GP1b, while maintain-
ing normal coagulative phenotypes. In addition, porcine proteins which provide positive and 
negative feedback to control the coagulation cascade do not function as efficiently upon the 
human coagulation targets, leading to dysregulation of the cascade. The targeting the porcine 
genome to express human regulatory proteins in porcine cells has been shown to help control 
human coagulation in response to exposure to the modified porcine materials [35].
8.5. Innate immune cells
Macrophages and neutrophils are two of the earliest host cell types to infiltrate xeno-organs. 
Both cell types are instrumental in the phagocytosis and destruction of pathogens during 
infection. During a xenorejection response, the damaged porcine cells release a variety of 
DAMPs which are recognized by the human innate cells, inducing phagocytic functions 
which further damage the xeno-organ and increasing production of additional proinflamma-
tory and other immune mediators which attract more innate immune cells [36, 37].
Similar to the molecular mismatch described above for vWF and coagulation, macrophages 
express the SIRPA receptor, which must interact with the surface receptor CD47 to prevent the 
target cell destruction by the macrophage. Thus, the CD47 receptor expressed on the cell surface 
binds to SIRPA to instruct the macrophage not to consume the target cell. In the case of porcine 
CD47, the interaction with human SIRPA appears to be unproductive and cannot inhibit the 
macrophage activity. Expression of the human form of CD47 in porcine cells has been shown to 
greatly reduce human macrophage activity directed against the porcine cells [38].
NK cells are functionally analogous to cytolytic T cells, and even share some mechanistic 
pathways for targeted cell destruction. NK cells express a collection of stimulatory and inhibi-
tory receptors on the cell surface, which engage conserved targets on the surface of target 
cells. The balance of activation and inhibition via combinatorial signaling determines whether 
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the NK cells are stimulated to kill or ignore the target cell. The target cell receptors, such as 
HLA-E, may be perturbed by pathogens or tumorigenesis, which is detected by the NK cells 
and the target cells eliminated [39].
In the case of xenotransplantation, the porcine cell receptors, although expressed normally, 
are not sufficiently well-conserved with their human counterparts and thus cannot inhibit NK 
cell attack. By expressing on porcine cells the human versions of receptors which stimulate 
the inhibitory receptors on NK cells, the damage may be averted. With careful genetic modi-
fication, the normal mechanisms for detection of infection or other dysfunction may be main-
tained, allowing normal NK functions while eliminating the xeno-specific destruction [40, 41].
8.6. Resolution of innate immune responses
There are a variety of mechanisms used to resolve innate immune reactions. Many of the 
soluble mediators of innate immunity have extremely short half-lives which allows them to 
dissipate quickly. In addition, immune receptors become increasingly desensitized to further 
stimulation during the course of the innate response, reducing reactions. A variety of nega-
tive regulators are also produced to further inhibit the innate effectors. All of these mecha-
nisms are in place to prevent over-reaction of the immune system and the destruction that it 
can cause once the pathogenic threat has been eliminated [42]. In the case of a xenorejection 
response, however, the “threat” that is recognized comes from every porcine cell and thus the 
innate response is never fully resolved without intervention. It may be possible to take advan-
tage of these resolution mechanisms to create porcine cells with an enhanced ability to curtail 
or end a human inflammatory response through careful genetic modification.
8.7. The adaptive immune system and xenorejection
The adaptive immune system is comprised of cellular and antibody components which rec-
ognize pathogens and develop highly specific responses, which can increase in specificity and 
effectiveness over time and exposure. The adaptive immune response also creates immuno-
logical “memory” to allow more rapid reactions should similar pathogens be encountered in 
the future. Because of the time required to develop specific responses, the adaptive immune 
system generally becomes more critical after the initial innate immune response [21].
8.8. Antigen presentation and T cells
Antigen presentation is a crucial mechanistic part of the adaptive immune response and plays 
a major role in the decision between immunity and tolerance for a given target. There are two 
main routes for antigen presentation to the immune system, reflective of the different classes 
of pathogen antigens, intracellular or extracellular.
Intracellular antigens, either natural cellular proteins or those derived from viral or bacte-
rial infection of cells, are enzymatically cleaved into peptides which bind to the ubiquitously 
expressed class I human lymphocyte antigens (HLA). The peptide-HLA class I complex is dis-
played on the cell surface where it can be surveyed by the binding of cytolytic T cells express-
ing T cell receptors (TCR) and CD8 co-receptors on the T cell surface. Similar to antibodies, 
TCRs are assembled combinatorially, creating a diversity of specificities for HLA-peptide 
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complexes, with only a small subset of TCRs binding to a given complex. Should a given CD8 
T cell be activated by the HLA-peptide complex, it will express a series of cytolytic molecules 
which kill the target cell. This system works due to the efficient T cell selection mechanisms 
applied during T cell development. After initial production of a rearranged TCR, the nascent 
T cell is tested in the thymus for inappropriate reactivity against cellular antigens. If the T 
cell survives the selection process, it exits to the body and theoretically will only be activated 
when it encounters and antigen that does not naturally exist in body, such as a peptide from 
a pathogenic organism, or a mutant peptide from an oncogenic cell [43].
Extracellular antigens can be any molecule taken up by a cell from its environment and 
degraded in lysosomes intracellularly. The resulting peptides are then loaded onto HLA class 
II molecules which, unlike HLA class I, are expressed on only a subset of immune-related 
cells. The class II HLA-peptide complex is recognized by a different T cell subset express-
ing TCRs with the co-receptor CD4. The CD4 T cell subset also undergoes thymic selection 
as observed with CD8 T cells, to eliminate recognition of self-antigens [44]. However, CD4 
T cells can be induced to create different phenotypes once they specifically recognize class 
II HLA-peptide complexes. A large variety of T cell subsets have been described, including 
production of helper T cells, which participate in the activation of B cells for the production 
of antigen-specific antibodies, or regulatory T cells, which act to inhibit the immune response 
[45]. The choice of outcomes is driven by the soluble mediators, such as cytokines, found in the 
local environment, and the collection of co-receptors expressed on the antigen presenting cells.
HLA itself is a significant direct contributor to rejection responses outside of its role in antigen 
presentation. As described above, T cells are selected for lack of recognition of self-antigens. 
This not only includes the recognition of self-peptides bound to HLA molecules, but of the 
HLA molecules themselves. Normally, T cells bearing TCRs with inappropriately high affin-
ity for binding HLA molecules, even in the absence of peptide, are eliminated early in T 
cell development. Because the human T cells have not been exposed to, or selected by, the 
class I or II swine lymphocyte antigens (SLA), a subset of human TCRs will bind to SLA and 
induce strong T cell activation, regardless of the peptide presented in the SLA [46]. As porcine 
cells are attacked by the human immune system, donor peptides are efficiently presented 
by human cells via HLA to human T cells as part of the normal human adaptive response. 
Conversely, depending upon the organ transplanted, there can also be donor T cells and anti-
gen presenting cells transferred which result in donor immune responses against the host 
tissues, referred to as graft versus host disease (GvHD) [47]. In all cases, the immune cells are 
responding normally, but in the setting of xenotransplantation can be extremely pathogenic 
due to the artificially high concentration of immunogenic targets present.
Because HLA matching is part of organ selection in allotransplantation, a frequent question 
is whether introduction of human HLA in place of porcine SLA would help overcome rejec-
tion. Although SLA ablation may be helpful in averting antibody-dependent damage, this 
approach does not resolve some of the challenges related to antigen presentation in xenore-
jection responses [29]. It is true that the human T cell binding directly to pig SLA could be 
eliminated by substitution of SLA with HLA, however, the HLA genes are highly polymor-
phic, hence the need to HLA match human patients. This means that for a given patient, a 
donor pig would need to be engineered to specifically express the HLA homologous to that 
patient, which would be limiting given the timelines necessary for production and validation 
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of genetically-modified pigs. In addition, in the normal situation human cells display human 
peptides in the HLA, the overwhelming majority of which will be conserved between a 
human donor and recipient, and thus much less likely to induce a response. If pigs were engi-
neered to express human HLA which is perfectly matched to the patient, the donor porcine 
cells could now be significantly more efficient at displaying porcine peptides to the human 
immune system and more rapidly induce T cell activation. Therefore, introduction of human 
HLA in place of porcine SLA may not provide a benefit without additional engineering.
Humans possess a number of pre-existing antibodies specific for porcine antigens which can 
contribute to the xeno-organ damage during HAR. As the donor tissue is damaged, the anti-
gens are released and presented to T cells as described above, causing the activation of helper 
T cells. These T cells interact with B cells in lymphoid organs, inducing the activation of any 
B cells which express antibodies specific for the xeno-antigens. This initiates the germinal 
center reaction, in which antigen-specific B cells rapidly proliferate and mutate their antibody 
sequences and are then progressively selected for improved antibody function. The resulting 
B cells expressing the affinity-matured antibodies exit the germinal center and can differenti-
ate further to plasma cells, which act as factories that can produce extraordinarily high levels 
of serum antibody [48]. These induced antibodies, like natural antibodies, further amplify 
AVR/AHXR and contribute to the destruction of the xeno-organ.
The de novo production of antibodies can be quite rapid and are a risk for the lifetime of the 
transplant whether for allo- or xenotransplantation. There are a number of drugs available 
for the control of B cell reactions. One of the most effective approaches is the depletion of B 
cells using antibody therapeutics such as Rituxan, specific for the CD20 surface molecule [49]. 
However, the constitutive ablation of host B cells will create long term immunosuppression 
and could be prohibitively expensive. Although highly related to CR in allotransplant, the B 
cell responses in xenotransplant are stronger and more challenging and likely to require more 
stringent therapeutic control.
9. Immune suppression and tolerance in xenotransplantation
Advancements in understanding of immune mechanisms in immune rejection have eluci-
dated a number of targets and pathways for intervention, and discovered a variety of small 
molecule and protein therapeutics for the suppression and manipulation of the immune sys-
tem. However, the restraint of the immune system required to prevent xeno-organ rejection 
places the patient at significant risk of infections, tumors and other diseases which are pre-
ventable by an intact immune system. Therefore, there is a growing interest in the application 
of immune tolerance mechanisms in the transplant setting.
Immune tolerance is the natural unresponsiveness of the immune system to targets which 
may otherwise create an immune response. As mentioned previously, there are many mecha-
nisms used by the immune system to identify non-self-antigens to prevent autoimmune dis-
eases. As the body of literature regarding the molecular basis of immune tolerance has grown, 
interest in testing tolerance mechanisms in xenotransplantation has also increased [50].
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Mixed chimerism is one route that has shown significant promise in both allo- and xeno-
transplant settings. This approach combines the transfer to the recipient of both the organ 
and hematopoietic cells from the donor. Typically, the patient is pre-treated with radiation 
or drugs to allow hematopoietic cell engraftment prior to the organ transplant. The combina-
tion of hematopoietic cells from host and donor allows cross-tolerance of host immune cells 
to donor tissue as well as donor immune cells to host tissue. Therefore, the resulting immune 
system is a combination of the donor and host, or a “mixed chimera,” which recognizes the 
donor organ and host tissue as “self” despite the differences in genetic origin [51].
A further refinement of mixed chimerism includes transplant of donor thymus into the recipi-
ent, allowing selection of host T cells via donor antigen presentation [52], suggesting that toler-
ance is T cell dependent. A large body of evidence points to the role of regulatory T cells (Treg) 
as a driver of immune tolerance. Treg cells are antigen-specific but upon binding of the specific 
HLA-peptide complex on antigen-presenting cells will produce a variety of immune inhibiting 
and tolerogenic factors. The Treg cells may be derived from either thymus selection (central tol-
erance) or selection in tissues (peripheral tolerance), with central tolerance believed to be more 
durable, and the conceptual basis for donor thymus transplantation in mixed chimerism [53].
A critical factor in the maintenance of tolerance is the balance between Treg and effector T 
cells over time. Any imbalance that increases the number of effector T cells can rapidly lead to 
immune rejection. If indeed the Treg population is the main active component of immune tol-
erance, then it may be desirable to specifically bolster the numbers of Treg cells transferred to 
the recipient to more greatly ensure that the balance is biased firmly toward tolerance. A num-
ber of groups have established protocols for the generation of Treg cells that are specific for 
xeno-organs and tissues through in vitro selections and expansions [54]. While this has been 
shown to have positive effects in allograft tolerance, the durability is variable and, worse, 
some studies have described conversion of Treg to effector T cells which then contribute to 
rejection [55]. Despite these concerns, mixed chimerism, with or without Treg supplementa-
tion, remains a potentially valuable approach to immune tolerance.
10. Genome engineering to improve xenotransplantation
The progress of xenotransplantation research in recent times has closely paralleled the 
advancement in genome engineering technologies. As the complexity of the engineering tool-
sets has increased, so too has the complexity of porcine genomic manipulations increased to 
address the immunological challenges described in previous sections.
Complex mammalian genome engineering has advanced much more rapidly in mice than in 
virtually any other species, including pigs. The reason for the rapid progress in mice is the 
availability of embryonic stem (ES) cells which can be maintained in culture for extended 
periods time and undergo extensive transfection/transduction protocols and drug selection 
without losing the ability to produce large numbers of fertile progeny via blastocyst injection 
[56]. Although several labs have made strides in this area, similarly manipulable and viable 
ES cells are not currently available for routine use in the generation of cloned pigs [57].
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The most common approach for production of genetically-modified pigs is very similar to the 
protocol described in the creation of “Dolly the sheep.” Briefly, the nucleus from a pig cell 
carrying the desired genome changes is extracted and introduced into a pig oocyte, which 
has previously had its own nucleus removed, and then induced to initiate embryogenesis 
using electrical and chemical induction, a process referred to as somatic cell nuclear transfer 
(SCNT). The newly-created cells are implanted into surrogate female pigs and allowed to 
develop to birth. Compared to genetically-modified mouse production, this process is sig-
nificantly less efficient and more costly, limiting the number of facilities capable of effectively 
carrying out this complex process [58].
A key factor in the success of SCNT is the source of the donor nucleus. These cells are typi-
cally primary cells derived from fetal sources. Extended culture, transfection, or drug selec-
tion of these donor cells can all cause a significant loss of viability for subsequent productive 
SCNT. Therefore, the approaches commonly used for mouse ES cell manipulation such as 
multigenic targeting and selections with various drugs over long periods in culture would 
not allow for production of modified pigs using SCNT. Similarly, any genome manipulations 
of pig cells must also maintain the viability of the cells for SCNT, which alters the approaches 
available compared with mice.
10.1. Gene knockouts
One of the earliest genome engineering approaches applied to pigs was introduction of gene 
knockouts (KO). For any given gene, mutations which remove or disrupt the coding sequence 
can eliminate the expression of the gene and, provided that the KO is not lethal, create an 
organism which is entirely missing the gene product. The introduction of gene KO technol-
ogy has been a key factor in the rapid advancement of the field of xenotransplantation [59].
As discussed above, there are several glycan molecules present in pigs which are absent in 
humans. These glycans are recognized by antibodies present in human serum which leads to 
rapid and extensive antibody-mediated damage to the porcine cells. Therefore, the elimination 
of the specific carbohydrate structures should help prevent human antibody recognition of the 
pig tissues. Unlike protein antigens which are directly coded by the DNA, glycosylation is due 
to the action of enzymes which create post-translational modifications of a variety of proteins 
produced by the cell. Therefore, glycosylation pathways must be examined to identify the key 
enzyme that creates the immunogenic glycan while otherwise leaving cellular metabolism intact.
The GGTA1 gene is responsible for creating the Gal alpha (1,3) Gal epitope in pigs. Although 
the specific reasons for this are unclear, human patients can express high levels of antibody 
specific for the Gal alpha (1,3) Gal epitope, presenting a major challenge to xenotransplanta-
tion [60]. The KO of the GGTA1 gene is one of the earliest genetic modifications of pigs for 
application in xenotransplantation, and results in greatly reduced human antibody recogni-
tion of porcine cells [61]. However, elimination of the GGTA1 gene alone has been shown to 
be insufficient due to a variety of other xenoantigens present in pig cells which are recognized 
by antibodies present in human serum. Generation of KO of CMAH [62], B4GALNT2 [28] 
and other xenoantigen genes have further decreased the reactivity of porcine cells to human 
serum. However, it is important to keep in mind that the greater the number of gene KO, 
especially when made in combination, may lead to detrimental effects on pig health.
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10.2. Gene insertions
The use of gene KO approaches is highly useful for eliminating xenoantigens but does not 
address the need for expression of human or synthetic versions of genes necessary for control 
or proper function of dysregulated pathways. This requires the ability to permanently intro-
duce heterologous DNA into the genome in a manner which maintains gene function.
The initial approach to gene insertions was simply random integration of DNA into the 
target genome. These genes are introduced from elsewhere and thus termed “transgenes” 
(TG). Once the ability to introduce DNA into mammalian cells was established using a vari-
ety of technological approaches, it became clear that over long-term culture a subset of cells 
could be isolated which have permanently incorporated the heterologous DNA. Because 
many transgenes do not provide a straightforward means to identify cells which have incor-
porated foreign DNA from the population that have not, TGs often include genes encoding 
drug resistance markers. In order for cells to survive drug treatment they must incorpo-
rate the resistance gene, greatly reducing the population to be screened, and increasing 
the chance of identifying cells which incorporate the TG of interest along with the drug 
resistance gene [63].
The integration of transgenes is rapid but relatively uncontrolled. Although there may be 
some preferences for integration site based upon chromatin accessibility, these are hard 
to predict and may be related to DNA breakage sites at which repair mechanisms for-
tuitously insert the transgene DNA [64]. The random nature of the insertions can create 
risks. For example, the same transgene inserted at different sites can yield highly variable 
results in expression. Furthermore, some insertions may be deleterious to cell function, 
causing them to grow more slowly or die off, or, if these cells are used for generation of 
animals in vivo, there is a possibility of insertions creating mutations, instability or even 
lethality.
Due to the risks of random integration, significant effort has focused on protocols to create 
targeted integration, or gene knock-in (KI), of heterologous DNA into the genome. This is 
accomplished in mice by taking advantage of ES cells which undergo homologous recombi-
nation. In this approach, the transgene of interest is flanked by DNA sequences that are iden-
tical to regions of the genome to be targeted. After introduction of the heterologous DNA, the 
regions of DNA sequence identity are aligned with the target sequence and the homologous 
recombination machinery creates crossover events to switch the endogenous sequence with 
the heterologous sequence. This approach is much less efficient than random integration of 
TG, therefore drug selection schemes often need to be employed to identify the relatively rare 
targeting events [64].
Homologous recombination is well-established for targeting in mice but requires ES cells 
which express the enzymes necessary for the targeting event. Unfortunately, porcine ES cells 
are not available that both possess homologous recombination function and can reliably gen-
erate cloned animals. For reasons that are not entirely clear, generation of ES cells competent 
for homologous recombination and cloning seems to be challenging for most species other 
than mice [57]. Therefore, alternate approaches are required for targeted integration in the 
pig genome [65].
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10.3. Tools for genome engineering
A number of novel enzymatic molecules have been created which help resolve the dilemma 
of targeted integration in porcine cells. Zinc Finger Nucleases (ZFN), Transcription Activator-
Like Effector Nuclease (TALEN) and Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) are all synthetic molecules based on genuine proteins which allow the 
precise targeting of genomic DNA based upon sequence [66–68]. In each case there are two 
functional components, a targeting module which recognizes a specific genomic sequence, 
and an enzymatic module which introduces a double-stranded DNA break at the target site. 
In the case of ZFN and TALEN, the targeting module is a complex array of protein sequences 
which have previously been shown to recognize specific DNA sequences and can be mixed 
in a modular way to bind to any desired sequence. Although both technologies have shown 
great success, the effort and cost required to identify a single functional molecule can be sig-
nificant. In contrast, the relatively more recently recognized CRISPR, and related prokary-
otic systems, is much more easily applied in mammalian cells. The DNA binding module in 
this case is RNA base-pairing to provide sequence specificity. The enzymatic module cleaves 
DNA, creating a double strand break similar to ZFN and TALEN. When heterologous DNA is 
present, the cellular repair machinery may use the synthetic DNA to repair the break, insert-
ing the TG at the desired genomic site. It is important to note that all of these systems, ZFN, 
TALEN or CRISPR, are essentially the same in that they introduce double strand DNA breaks 
at a selected site in the genome and do not directly affect the rate of DNA insertion. Therefore, 
it is often necessary to include selection schemes for identification of the modified cells. The 
greater efficiency and ease of use of these systems, CRISPR in particular, has allowed targeted 
insertion of DNA into genomes that were not previously able to be modified [69].
Due to the challenges of creating genomic modifications in porcine primary cells while 
maintaining their viability for SCNT, more efficient engineering methods are desirable. One 
approach to enhance efficiency is to target a specific region of DNA, called a landing pad, 
with multiple genes at once. By inserting a DNA vector bearing multiple therapeutic genes at 
once, a large amount of breeding and testing can be circumvented using a single event. This 
approach has the added advantage of avoiding inefficient crossbreeding necessary to bring 
loci from distinct chromosomes together in one lineage. When combined with the use of tools 
such as ZFN, TALEN and CRISPR more rapid progress in the genetic modification of animals 
has been greatly facilitated [70].
11. Conclusions and future prospects
The increasing sophistication and accessibility of genome engineering toolsets and deeper under-
standing of immunological rejection mechanisms has allowed greater advancement in xeno-
transplantation than ever before. A key question is just how many genetic changes are required 
in order to make a pig organ suitable for transplantation? While the critical experimental data 
needed for such an assessment is still accumulating, it is clear that the number of alterations 
required for one organ may be different from another. For example, xeno-hearts with relatively 
minimal genetic modifications have demonstrated months to years survival in transplantation 
studies with non-human primates, whereas xeno-lungs with more extensive modifications have 
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yet to survive more than a few weeks. This is due to the relative differences in structure and func-
tion of organs, the resilience to trauma, and susceptibility to rejection responses. Furthermore, 
tolerance mechanisms may be able to supplant the need for some genetic modifications, and 
thus the specific protocols and treatments will govern the ultimate complement of alterations.
The immediate need in xenotransplantation is to define the specific genetics required for xeno-
organ survival, however, it is possible to project further enhancements such that porcine organs 
may be superior to human organs for human transplant. Synthetic biology approaches have 
created novel genetic circuits which can react in real time to human immune responses, induc-
ing counter-reactions in the porcine cells to circumvent and tolerize the xeno-organ against 
human rejection. Furthermore, xeno-organs may be engineered to express protein therapeutics 
to further control human immunity while saving hundreds of thousands of dollars in expensive 
biotherapeutic treatments. Thus, the first version of pigs appropriate for xenotransplantation 
are likely to be further refined and improved to create increasingly useful rejection-free organs.
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